| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TPG-H52E5 | Human | Unconjugated Human TPBG / 5T4 Protein, His,Avitag™ |  |
|
|
| TPG-H82Eb | Human | Biotinylated Human TPBG / 5T4 Protein, His,Avitag™ |  |
|
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SYD-1875 | SYD-1875 | Phase Ⅰ | Synthon | Solid tumours | Details |
| Prostate cancer vaccine, inactivated viral (University of Oxford) | Phase Not Specified | University of Oxford | Prostate cancer | Details | |
| CME-548 (Oxford biomedica/Pfizer) | CME-548 | Preclinical | Oxford BioMedica, Pfizer | Cancer | Details |
| GEN-1044 | GEN-1044 | Phase Ⅱ | Genmab | Solid tumours | Details |
| OXB-301 | OXB-301; SAR-109659 | Phase Ⅲ | Oxford BioMedica, Cardiff University, University College London, Wales Cancer Trials Unit | Clear cell renal cell cancer (ccRCC) | Details |
| PET imaging agent (ImaginAb/Oxford BioMedica) | Preclinical | ImaginAb, Oxford BioMedica | Ovarian cancer | Details | |
| PF-06263507 | PF-06263507 | Phase Ⅰ | Oxford BioMedica, Pfizer | Solid tumours | Details |
| Naptumomab estafenatox | ABR-217620; TTS-CD3,ABR217620,TTSCD3 | Phase Ⅲ | Active Biotech | Advanced renal cell carcinoma (RCC) | Details |
This web search service is supported by Google Inc.
A-Z